Placebo of valsartan

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Acute Myocardial InfarctionChronic Heart Failure (CHF)

Phase 3

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

CompletedNCT02884206

Novartis PharmaceuticalsChronic Heart Failure (CHF)

Start: 2016-11-23End: 2022-05-16Updated: 2024-08-06

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

CompletedNCT02924727

Novartis PharmaceuticalsAcute Myocardial Infarction

Start: 2016-12-09End: 2021-02-26Updated: 2023-06-22

Related Papers

Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials.

2024-10-016 citations

Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.

2024-03-0111 citations

Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI

Journal of the American Heart Association2023-08-2313 citations

Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial

Circulation Heart Failure2023-05-0142 citations

The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial

Circulation2022-11-0227 citations

Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy

Circulation2022-10-0356 citations

Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

New England Journal of Medicine2021-11-10274 citations

Do sacubitril/valsartan affect neurocognitive function?

Annual for Hospital Pharmacy2021-10-14

Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions.

2020-10-1623 citations

Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.

2020-01-1613 citations